Recent progress on chikungunya virus research

被引:0
作者
Wenxi An [1 ,2 ]
Ningning Ge [1 ]
Yilin Cao [1 ,3 ]
Jin Sun [1 ]
Xia Jin [1 ]
机构
[1] Viral Disease and Vaccine Translational Research Unit, CAS Key Laboratory of Molecular Virology andImmunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences
[2] Department of Biochemistry and Molecular Biology, Pennsylvania State University, State College
[3] College of Pharmaceutical Sciences, Jilin University
关键词
chikungunya virus(CHIKV); epidemiology; molecular virology; host immune response; vaccine development;
D O I
暂无
中图分类号
R373 [人体病毒学(致病病毒)];
学科分类号
100103 ; 100705 ;
摘要
Chikungunya virus(CHIKV) is an arbovirus transmitted by Aedes mosquitos in tropical and subtropical regions across the world. After decades of sporadic outbreaks, it re-emerged in Africa,Asia, India Ocean and America suddenly, causing major regional epidemics recently and becoming a notable global health problem. Infection by CHIKV results in a spectrum of clinical diseases including an acute self-limiting febrile illness in most individuals, a chronic phase of recurrent join pain in a proportion of patients, and long-term arthralgia for months to years for the unfortunate few. No specific anti-viral drugs or licensed vaccines for CHIKV are available so far. A better understanding of virus-host interactions is essential for the development of therapeutics and vaccines. To this end, we reviewed the existing knowledge on CHIKV's epidemiology, clinical presentation, molecular virology, diagnostic approaches, host immune response, vaccine development, and available animal models. Such a comprehensive overview, we believe, will shed lights on the promises and challenges in CHIKV vaccine development.
引用
收藏
页码:441 / 453
页数:13
相关论文
共 32 条
[1]  
Global expansion of chikungunya virus: mapping the 64-year history[J] . Braira Wahid,Amjad Ali,Shazia Rafique,Muhammad Idrees.International Journal of Infectious Diseases . 2017
[2]   Zika Virus Pathogenesis and Tissue Tropism [J].
Miner, Jonathan J. ;
Diamond, Michael S. .
CELL HOST & MICROBE, 2017, 21 (02) :134-142
[3]   Identification of Functional Determinants in the Chikungunya Virus E2 Protein [J].
Weber, Christopher ;
Berberich, Eva ;
von Rhein, Christine ;
Henss, Lisa ;
Hildt, Eberhard ;
Schnierle, Barbara S. .
PLOS NEGLECTED TROPICAL DISEASES, 2017, 11 (01)
[4]  
Laboratory Diagnosis of Chikungunya Virus Infections and Commercial Sources for Diagnostic Assays[J] . Barbara W. Johnson,Brandy J. Russell,Christin H. Goodman.Journal of Infectious Diseases . 2016 (supp)
[5]   Chikungunya vaccines in development [J].
Schwameis, Michael ;
Buchtele, Nina ;
Wadowski, Patricia Pia ;
Schoergenhofer, Christian ;
Jilma, Bernd .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (03) :716-731
[6]  
Dengue, chikungunya and Zika co-infection in a patient from Colombia[J] . Wilmer E. Villamil-Gómez.Journal of Infection and Public Health . 2015
[7]  
French guidelines for the management of chikungunya (acute and persistent presentations). November 2014[J] . F. Simon,E. Javelle,A. Cabie,E. Bouquillard,O. Troisgros,G. Gentile,I. Leparc-Goffart,B. Hoen,F. Gandjbakhch,P. Rene-Corail,J.-M. Franco,E. Caumes,B. Combe,S. Poiraudeau,F. Gane-Troplent,F. Djossou,T. Schaerverbeke,A. Criquet-Hayot,P. Carrere,D. Malvy,P. Gaillard,D. Wendling.Médecine et Maladies Infectieuses . 2015 (7)
[8]   Dengue [J].
Guzman, Maria G. ;
Harris, Eva .
LANCET, 2015, 385 (9966) :453-465
[9]  
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial[J] . Katrin Ramsauer,Michael Schwameis,Christa Firbas,Matthias Müllner,Robert J Putnak,Stephen J Thomas,Philippe Desprès,Erich Tauber,Bernd Jilma,Frederic Tangy.The Lancet Infectious Diseases . 2015 (5)
[10]   Development of a multiplex real-time RT-PCR assay for simultaneous detection of dengue and chikungunya viruses [J].
Cecilia, D. ;
Kakade, M. ;
Alagarasu, K. ;
Patil, J. ;
Salunke, A. ;
Parashar, D. ;
Shah, P. S. .
ARCHIVES OF VIROLOGY, 2015, 160 (01) :323-327